Collectively, our findings identify TMEJ as the preferred mechanism for repairing APOBEC3A-induced DSBs and establish Polθ inhibition as a novel promising strategy to eliminate cancer cells with APOBEC3A activity. The gene discussed is APOBEC3A; the disease is cancer.